TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting

...

Related Keywords

United States ,Poland ,Cambridge ,Cambridgeshire ,United Kingdom ,China ,Japan ,Polish ,America ,American ,Suresh Ramalingam ,Susan Galbraith ,Cerner Cancermpact ,Daiichi Sankyo ,International Agency For Research On Cancer ,American Cancer Society ,Lung Ambition Alliance ,Winship Cancer Institute Of Emory University ,Lungevity Foundation ,Single Institution Study ,Astrazeneca ,World Health Organisation ,Executive Director ,Winship Cancer Institute ,Emory University ,Executive Vice President ,Prescription Information ,Patient Information ,South America ,Rare Diseases ,International Agency ,Lung Fact ,Accessed February ,What Is Lung ,Clinical Oncology Provisional Opinion ,Epidermal Growth Factor Receptor ,Mutation Testing ,Kinase Inhibitor ,Histological Samples ,Small Cell Lung Cancer ,Systematic Review ,Intj Clin Exp ,Lung Cancer ,Available Methods ,Their Use ,Tumour Tissue ,Mediated Resistance ,Markets ,